Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 29, 2021 9:39am
271 Views
Post# 34175337

RE:SPECTRAL MEDICAL ANNOUNCES U.S. FDA APPROVAL OF TIGRIS TRIAL

RE:SPECTRAL MEDICAL ANNOUNCES U.S. FDA APPROVAL OF TIGRIS TRIALI like to accentuate the positive as much as the next guy, but even I am surprised by your misleading stockhouse post headline...


nevertheless further down is the most encouraging bit...

"we are encouraged by the current mortality results, which exceed expectations.”

...always nice words to hear when you are an investor in a company running a Confirmatory, Open Label Trial !


Now lets see how the enrollment rate increases given:
  • change to enrollment criteria (25-50% increase in enrollment expected)
  • finally 15 sites up and running (another 25 % increase in sites)
  • more committed locations (hard to measure the increase from that)
  • fewer Covid-19 challenges in the ICU (at least for now)
  • mounting real world evidence that PMX-HP may actually help Covid-19 patients who develop endotoxemia/Sepsis.

MM

<< Previous
Bullboard Posts
Next >>